What You Should Know
- AI-native life sciences platform Cheiron has secured $8M in seed funding led by Menlo Ventures, with Venky Ganesan joining the board.
- Strategic backers include Moderna co-founder Robert Langer, former Pfizer CMO Freda Lewis-Hall, Chai Discovery CEO Josh Meier, former Starbucks CEO Laxman Narasimhan, and former Apple AI chief John Giannandrea.
- Cheiron is designed to replace fragmented spreadsheets, papers, and filings by representing an entire drug development lifecycle as a single, connected, and auditable operating system.
- Platform center-point that connects global biomedical, clinical, regulatory, patent, and commercial data to allow real-time cross-referencing and hypothesis stress-testing.
- Rapid adoption within six months of launch across tens of thousands of biopharma professionals, including top-five South Korean pharmaceutical giant Boryung.
Builds the Operating System for Drug Programs
The biopharmaceutical research, clinical development, and life sciences software markets are confronting a major operational challenge. Every year, billions of dollars are poured into advancing promising therapeutic candidates, yet the fundamental unit of value—the drug program itself—has never existed as unified software.
Instead, critical knowledge is scattered across fragmented systems. Experimental results, clinical trial data, regulatory correspondences, competitive patent filings, and strategic assumptions reside in disconnected silos and human memory.
When drug development teams need to make high-stakes operational or clinical decisions, they spend weeks manually reconstructing context rather than advancing therapies.
To solve this knowledge fragmentation and build a unified system of record, Cheiron leverages advances in generative AI and structured knowledge representation to model the live, interconnected state of a drug program within a single software architecture.
The Life Sciences Knowledge Graph (LKG)
At the core of Cheiron’s platform is its proprietary Life Sciences Knowledge Graph (LKG)—a structured intelligence layer built to unify global clinical, biomedical, regulatory, patent, and commercial evidence into a single model.
Rather than acting as a standard search engine, the platform enables biopharma teams to reason over complex hypotheses and operational decisions:
- Cross-Workflow Inferences: Automatically cross-references clinical trial designs against regulatory precedents to identify approval roadblocks early.
- Discrepancy & Risk Detection: Surfacing contradictions between published scientific literature and competitor patent filings.
- Hypothesis Stress-Testing: Testing mechanism-of-action assumptions against a real-time graph of global biomedical evidence.
“Every important decision in drug development depends on understanding what is known, what is assumed, what remains uncertain, and what has already been decided,” stated Minseok Bae, CEO and co-founder of Cheiron. “We built Cheiron to make that state visible for the first time, so teams can spend less time assembling information and more time advancing therapies.”
